Presentations & Publications

AACR2019-keynote-046-adxs-psa-plus-pembrolizumab-metastatic-castration-resistant-prostate-cancer

KEYNOTE-046 AACR 2019 Abstract

Presentation

KEYNOTE-046: ADXS-PSA Plus Pembrolizumab in Metastatic Castration-Resistant Prostate Cancer

ASCO 2018

Presentation

Molecular signatures of combination immunotherapy of prostate cancer using a Listeria-based PSA vaccine and radiation

SITC, November 13, 2017

Presentation

Combination immunotherapy of murine prostate cancer using a Listeria-based PSA vaccine: immune correlates of efficacy and resistance development

SITC, November 13, 2017

Presentation

ADXS-PSA immunotherapy increases the magnitude and quality of prostate cancer-antigenspecific T cell responses in patients with metastatic castration-resistant prostate cancer

SITC, November 13, 2017

Presentation

Persistence of expanded TCRß clonotypes is associated with clinical activity of ADXS-PSA immunotherapy in metastatic castration-resistant prostate cancer

CRI-CIMT-EATI-AACR, September 9, 2017

Presentation

Gene expression profiles associated with stable disease in metastatic castration resistant prostate cancer patients treated with ADXS-PSA immunotherapy

CRI-CIMT-EATI-AACR, September 9, 2017

Presentation

2017 Investor Analyst Day

June 12, 2017

Presentation

Phase 1/2 study of ADXS31-142 alone and in combination with pembrolizumab in patients with previously treated metastatic castration-resistant prostate cancer (mCRPC): The KEYNOTE-046 trial

SITC, November 5, 2015

Publication

Combined immunotherapy with Listeria monocytogenes-based PSA vaccine and radiation therapy leads to a therapeutic response in a murine model of prostate cancer.

Published in Cancer Immunology Immunotherapy, December 2012

Publication

Immune Response and Immunotherapy: Live Attenuated Listeria monocytogenes (Lm)-LLO Immunotherapy for the Treatment of Prostate Cancer

Published in Current Cancer Therapy Reviews, November 1, 2012

Publication

Development of a Listeria monocytogenes based vaccine against prostate cancer

Published in Cancer Immunology Immunotherapy, February 14, 2008